ReviewFuture cardiology2010
Implementing genotype-guided antithrombotic therapy.
Review in Future cardiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01318057 (Pharmacogenetics of Warfarin in Puerto Rican Patients Using a Physiogenomics Approach.), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenetics of Warfarin in Puerto Rican Patients Using a Physiogenomics Approach.
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- Challenges and prospects ofFrontiers in pharmacology · 2026Review
- Anti-platelet Therapy Resistance - Concept, Mechanisms and Platelet Function Tests in Intensive Care Facilities.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2016Article
- Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.Drug metabolism and personalized therapy · 2015Review
- Individualized medicine enabled by genomics in Saudi Arabia.BMC medical genomics · 2015Review
- Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans.Puerto Rico health sciences journal · 2014Observational
- African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases.Evolution, medicine, and public health · 2013Article
- Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients.Pharmacogenomics · 2012Article
- Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.The pharmacogenomics journal · 2012Article
- Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.The Annals of pharmacotherapy · 2012Article
- Antiplatelet resistance in stroke.Expert review of neurotherapeutics · 2011Review
- CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.Clinica chimica acta; international journal of clinical chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Genotyping has the potential to improve the efficacy and safety of major antithrombotic drugs. For warfarin, the stable maintenance dose varies from 1-10 mg/day. The VKORC1 -1639G>A allele and the CYP2C9*2 and *3 alleles (cumulative frequency: 90% in Asians, 65% in Europeans and 20% in Africans), explain 45% of response variability in European and 30% in African populations. The large clinical trials COAG and EU-PACT will define the extent to which pharmacogenetic dosing affects the safety and efficacy of warfarin and coumarin derivatives. The platelet inhibitor clopidogrel requires activation by the CYP2C19 enzyme. CYP2C19*2 and *3 alleles (cumulative frequency: 20-50%) produce null enzyme activity, and their presence attenuates platelet inhibition and increases cardiovascular events. The US FDA-mandated drug labeling recognizes the relevance of genotyping in the selection and dosing of both warfarin and clopidogrel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.